glp-1 smoking cessation IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target BIO: Can GLP-1s help you

UV light catalyzes copper ion oxidation, which breaks the peptide-copper coordination bond and renders the compound biologically inactive

The bacteria in your gut ferment the fiber from your diet to produce SCFAs

Warning signs that should prompt a clinical evaluation include: memory loss that disrupts daily life, increased difficulty planning or problem-solving, confusion about time or place, difficulty completing familiar tasks, changes in mood or personality, and withdrawal from social activities

A comprehensive meta-analysis revealed that there was no significant difference in the risk of acute pancreatitis associated with the group receiving GLP-1 agonists versus the placebo group (Peto OR [95% CI] 1.05 [0.781.40], p = 0.76 and 1.12 [0.771.63], p = 0.56, respectively) (Cao, et al., 2020)